Medtech Industry Faces Tariffs Despite Pleas for Exemption

Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.

Blue shipping container labeled "TARIFFS" sitting on US flag.
(Tama2U/Shutterstock)

Medical devices, diagnostics and equipment will be subject to tariffs announced by President Donald Trump on Wednesday despite industry pleas to the contrary, and even though the pharmaceutical industry was spared.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Medtech Insight

Keeping Germany’s Medtech Industry Apprised, Advised and Incentivized in Turbulent Times

 
• By 

A change of government, hospital reform and a drive towards healthcare digitization are keeping German medtech manufacturers on their toes. Making the MDR more user-friendly and winning support for a medtech strategy are arguably bigger priorities. US export tariffs have also pushed their way onto the agenda. BVMed chief executive Marc-Pierre Möll puts it all into context.

Indian Medtechs Call US Tariffs A Challenge To Growth And Seek Reciprocal Regulatory Access

 
• By 

India’s medical technology industry is raising the alarm over steep new US tariffs on imported medical devices. It argues for structural change to address “unequal regulatory access” and non-tariff barriers.

J&J Medtech’s FDA-Cleared DUALTO System Prepares For Future Use With OTTAVA Robotic Platform

 
• By 

DUALTO’s double-module option provides enhanced flexibility while cutting down on equipment clutter. Compared to traditional setups, the system reduces OR footprint by 46%, helping staff reclaim space and optimize surgical workflows.

OneCell Diagnostics’ Mohan Uttarwar Discusses Liquid Biopsy Breakthroughs And The Future Of Precision Oncology

 
• By 

OneCell’s co-founder Uttarwar discusses clinical validation milestones, CLIA certification, and the startup’s strategic roadmap – from hospital partnerships in India to biopharma collaborations in the US.

More from Policy & Regulation

Medtech Strategy Must Be Priority, German Diagnostics Firms Tell Government

 
• By 

Germany’s incoming coalition government has reacted positively to industry’s calls for a dedicated medtech strategy to boost economic growth. Faster digitization, lower energy costs and “IVDR 2.0” are also on the in vitro diagnostic industry’s agenda.

FDA Reverses Course, Allows Some Telework For Reviewers

 

The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.

Opportunity For Medtech To Contribute To EU Cybersecurity Recommendations

 

The deadline for comments is 30 June 2025